Haleon was among the FTSE 100 index top performers after it said that pretax profit for 2023 slightly rose supported by better-than-expected sales, with positive volume, price and organic growth ...

Haleon HLN0.02%increase; green up pointing triangle posted a higher pretax profit for 2024 despite lower revenue, and said it expected further organic revenue and profit growth this year. The ...

Haleon sells health products internationally with stable operations and modest growth through a good performance in oral health products, and growth in Asia Pacific. The company's financials have ...

I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered ...

“It’s crazy to say that, isn’t it?” A new collaboration between Microsoft and global consumer health company Haleon aims to make health product information more accessible for people who are blind or ...

Haleon PLC HLN shares rose 1.55% to £3.86 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.64% to 8,328.60. Haleon ...

Haleon PLC HLN shares slid 1.91% to £3.86 Monday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.10% to 8,638.01. Haleon PLC ...

Haleon, a global consumer health company, is investing $54.2 million to upgrade its research & development (R&D) facility in Richmond, Virginia. The modernization will enable the company to expand ...

(Reuters) - Consumer healthcare company Haleon said on Wednesday it will invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new ...

RICHMOND, Va. — Haleon, a global company behind home healthcare products like Advil, Tums and Aquafresh, announced Monday its plan to upgrade its Richmond research and development facility.